Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against Dengue and Other FlavivirusesGlobeNewsWire • 08/24/21
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021GlobeNewsWire • 08/05/21
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors MoneyThe Motley Fool • 08/04/21
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 PatientsBenzinga • 06/30/21
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with RocheGlobeNewsWire • 06/16/21
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical AffairsGlobeNewsWire • 06/15/21
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of DirectorsGlobeNewsWire • 05/20/21
Atea Pharmaceuticals, Inc.'s (AVIR) CEO Jean-Pierre Sommadossi on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Atea Pharmaceuticals to Host First Quarter Financial Results Conference Call on May 13, 2021GlobeNewsWire • 05/06/21
Atea Pharma Stock Is Trading Higher As AT-527 Study In COVID-19 Moves Forward With DosingBenzinga • 04/29/21
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19GlobeNewsWire • 04/29/21
Atea Pharmaceuticals (AVIR) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 04/22/21
Atea Pharmaceuticals (AVIR) Is in Oversold Territory: What's Next?Zacks Investment Research • 04/16/21
Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/30/21
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021GlobeNewsWire • 03/23/21
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic InfectionsGlobeNewsWire • 03/06/21
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in JapanGlobeNewsWire • 02/19/21